Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide

Add time:07/11/2019    Source:sciencedirect.com

ObjectiveTo evaluate the treatment effects of the IL-6R antibody tocilizumab and cyclophosphamide (CTX) in patients with Takayasu arteritis (TA) and explore the mechanism by analyzing their effects on various cytokines.

We also recommend Trading Suppliers and Manufacturers of (6R)-6-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (cas 187235-55-8). Pls Click Website Link as below: cas 187235-55-8 suppliers

Prev:Process Intensification of Tetrazole reaction through tritylation of 5-[4′-(Methyl) Biphenyl-2-Yl] using microreactors
Next:Synthesis of polysubstituted phenyl acetates via FeCl3-mediated domino reaction of 2-(aryl(piperidin-1-yl)methyl)phenols and 1,3-diketones)